The Bayer-Monsanto Deal Won't Eat the Cannabis Industry. Yet.

Error message

The MailChimp PHP library is missing the required GuzzleHttp library. Please check the installation notes in README.txt.

Warning message

The subscription service is currently unavailable. Please try again later.

The news that Monsanto is being bought by Bayer probably won’t be well received in the cannabis sector. The deal brings together two research powerhouses that, reportedly, have long eyed cannabis as a possible new business. The worry is that the combined firm will have the financial and political influence to do to cannabis what it has already done to corn, tobacco, and other cash crops—namely, use pricy patented cannabis seeds (Roundup Ready Blue Dream, anyone?) that favor large-scale operators and rigidly control how all cannabis farmers farm. The merger, in other words, could be the first step toward Big Cannabis.

In truth, it’s far from certain just how worried “small cannabis” should be. On the one hand, Bayer clearly has designs on the multi-billion-dollar cannabis market. The German firm has been working with GW Pharmaceuticals on a cannabis-based medicinal extract since 2003. And while Monsanto says it “has not and...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.